Spotlighting Branched Dual Payload Linker Design to Enable One-Step Conjugation to Bispecific Antibodies - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Spotlighting Branched Dual Payload Linker Design to Enable One-Step Conjugation to Bispecific Antibodies

2:30 pm - Monday 12th October 2026

Designing a branched linker–payload architecture that incorporates two distinct payloads into a single, preassembled conjugation moiety
Enabling one-step attachment of the branched dual payload construct to a bispecific antibody, simplifying the generation of dual payload bispecific ADCs
Demonstrating the approach through the preclinical profile of TJ102 and its recent IND clearance

Speakers:

Tony Chen

Tony Chen

Founder & Chief Executive Officer

Phrontline Biopharma